Pricing Log in Create free account
Friday 6 November 2026 Export NEO’s income statement to Excel — free account

NeoGenomics, Inc.

NEO Healthcare Diagnostics & Research

NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.

Revenue
+11.4%
EPS
+72.1%
Free cash flow
−3,724.2%
Total debt
+10.9%

Quarter to September 2026, against a year earlier

16.55 0.60 −3.50%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−68.4×
Dividend yield
—
F-score
4/9
Altman Z
1.79
Beneish M
−2.68
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.72
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — 1 — — — — 2 — 1 — — —
Insider Ownership 1.31%

Capital & Financial Ratios $m

Size
Market Cap 2,130.00
Revenue ttm 787.75
Net income ttm (32.29)
Free cash flow ttm (26.52)
Net debt Q 239.56
Valuation
P/E 0.00
Forward P/E (68.40) (negative: loss-making)
Price / sales 2.70
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.66
Financial health
Current ratio Q 3.53 (at or above 1.5: strong)
Debt / equity Q 0.47 (at or below 0.5: strong)
Interest coverage Q (6.27)
Growth
Revenue growth Q +11.43% (above 0%: growing)
Operating income growth Q +70.60% (above 0%: growing)
EPS, this year +70.00% (at or above 15%: strong)
EPS, next year A +53.43% (at or above 15%: strong)
Revenue, next year A +11.12% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +49.79% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.3×, against a ten-year median of 3.7×; over the ten years it ranged from 1.4× in 2025 to 12.9× in 2020.
P/S against its own 10 years 24.68%
10-year low 10-year high
P/B against its own 10 years 44.92%
10-year low 10-year high
EV/Sales against its own 10 years 34.43%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 415 387 160 139
Receivables 131 151 159 213
Inventory 24 27 29 26
Other 8 12 7 9
597 596 376 410
2023 2024 2025 Q'26
Payables 20 22 23 33
ST’ Debt — 201 — —
Other 2 0 1 0
96 301 88 116

Compound Annual Growth %

10y 5y 3y
Sales 21.97% 10.35% 12.58%
Cash Flow (1.99%) 29.07% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 14.85% 3.80% (5.71%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.06 Actual 0.07

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.04 0.06 Beat by 0.02
Q1 FY26 0.00 0.01 Beat by 0.01
Q2 FY26 0.03 0.05 Beat by 0.02
Q3 FY26 0.06 0.07 Beat by 0.01
Q4 FY26 0.06 — Reports 16 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.13) 0.02 (0.06) — —
’25 (0.20) (0.35) (0.21) (0.08) (0.84)
’24 (0.21) (0.15) (0.14) (0.12) (0.62)
’23 (0.25) (0.19) (0.15) (0.11) (0.70)
’22 (0.40) (0.28) (0.30) (0.18) (1.16)
’21 (0.19) 0.59 (0.17) (0.34) (0.07)
’20 (0.07) (0.06) 0.02 0.13 0.04
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 187 202 209 — —
’25 168 181 188 190 727
’24 156 165 168 172 661
’23 137 147 152 156 592
’22 117 125 129 139 510
’21 116 122 121 126 484
’20 106 87 125 126 444
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) 20 (9) — —
’25 (25) 20 9 1 5
’24 (26) 14 9 10 7
’23 (13) (2) (5) 18 (2)
’22 (29) (17) (16) (4) (66)
’21 2 (1) (8) (20) (27)
’20 (7) 2 1 6 1
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) 12 (21) — —
’25 (30) 14 1 (4) (20)
’24 (31) 1 (2) (2) (34)
’23 (23) (9) (10) 11 (31)
’22 (37) (15) (24) (8) (85)
’21 (14) (23) (23) (32) (91)
’20 (12) (3) (7) (6) (28)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 232 240 277 409 444 484 510 592 661 727 788 +13.5% 808 887 969 +10.0%
Gross margin, % 42.32 42.44 45.99 48.15 41.83 38.62 36.86 41.34 43.92 43.21 44.77 +0.9 pt
EBT (8) (3) 4 4 (14) (15) (159) (97) (81) (110) (36) +34.1%
EBT margin, % (3.38) (1.10) 1.38 0.89 (3.16) (3.11) (31.26) (16.41) (12.21) (15.16) (4.59) (11.8) pt
Net income (6) 0 3 8 4 (8) (144) (88) (79) (108) (32) +37.5%
Per share, $
Per share, $ Revenue 2.99 3.02 3.23 4.07 4.09 4.04 4.10 4.71 5.22 5.68 6.13 +7.4%
Earnings (0.39) (0.14) 0.03 0.08 0.04 (0.07) (1.16) (0.70) (0.62) (0.84) (0.25) +8.9%
Cash flow 0.28 0.23 0.52 0.23 0.01 (0.22) (0.53) (0.02) 0.06 0.04 0.03 (19.2%)
Capex (0.10) (0.17) (0.17) (0.20) (0.27) (0.53) (0.15) (0.23) (0.32) (0.19) (0.24) +8.0%
Free cash flow 0.18 0.05 0.36 0.03 (0.25) (0.76) (0.68) (0.24) (0.27) (0.15) (0.21) n/m
Book value 2.11 2.17 3.74 5.05 6.39 9.24 8.03 7.50 7.12 6.53 6.23 +13.4%
Shares, m 78 79 86 100 109 120 124 126 127 128 129 +5.7%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 417.86 1,794.67 0.00 0.00 0.00 0.00 0.00 0.00 221.3
P/S 2.89 2.88 3.90 7.19 13.15 8.45 2.22 3.38 3.16 2.07 2.70 4.9
P/B 4.09 4.03 3.37 5.79 8.42 3.69 1.13 2.13 2.31 1.80 2.66 3.7
EV/Sales 3.27 3.25 4.25 7.01 12.89 8.50 2.42 3.60 3.39 2.60 3.26 5.1
EV/FCF 54.37 179.44 38.58 858.01 (207.22) (45.32) (14.55) (69.39) (65.86) (95.87) (96.87) 63.2
Cash, $m
Cash, $m Operating cash flow 21 18 45 23 1 (27) (66) (2) 7 5 4 (14.5%)
Capex (8) (14) (14) (20) (29) (64) (19) (29) (41) (25) (31) +14.2%
Free cash flow 14 4 30 3 (28) (91) (85) (31) (34) (20) (27) n/m
Balance, $m
Balance, $m Working capital 41 49 43 227 376 594 515 501 295 288 294 +24.3%
Net debt 89 87 96 (73) (119) 25 104 123 154 182 240 +8.3%
Shareholders’ equity 164 172 320 507 694 1,108 998 942 902 837 801 +19.9%
Returns, %
Returns, % ROA (8.95) (3.21) 1.43 1.32 0.49 (0.58) (7.99) (5.14) (4.74) (7.21) (2.35) +1.7 pt
ROIC 0.53 0.70 1.51 1.87 (1.52) (6.55) (8.94) (6.33) (5.45) (7.11) (2.97) (7.6) pt
ROE (16.51) (6.52) 2.47 1.93 0.69 (0.93) (13.70) (9.07) (8.54) (12.42) (3.94) +4.1 pt
People
People Employees 968 1,030 1,500 1,700 1,700 2,000 2,100 2,100 2,200 2,500 — +11.1%
Revenue/emp, $m 0.24 0.23 0.18 0.24 0.26 0.24 0.24 0.28 0.30 0.29 — +2.2%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

NeoGenomics, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ADPT Adaptive Biotechnologies Corporation $4.3B — (loss-making) — (loss-making) −10.72% (below 0%: shrinking) −66.67% (below 0%: shrinking) +201.86% (above 0%: growing) 76.24% (0.54%) Compare
CDNA CareDx, Inc. $4.0B 30.9× 36.2× +39.29% (above 0%: growing) +1,133.33% (above 0%: growing) −68.62% (below 0%: shrinking) 71.09% 5.82% Compare
NEO NeoGenomics, Inc. $2.1B — (loss-making) — (loss-making) +11.43% (above 0%: growing) n/m −3,724.21% (below 0%: shrinking) 46.16% (3.79%)
VCYT Veracyte, Inc. $1.9B 15.2× 45.2× +15.08% (above 0%: growing) +62.50% (above 0%: growing) −9.63% (below 0%: shrinking) 70.58% 10.92% Compare
WGS GeneDx Holdings Corp. $1.9B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
PSNL Personalis, Inc. $1.7B — (loss-making) — (loss-making) +76.59% (above 0%: growing) n/m −15.54% (below 0%: shrinking) 25.67% (138.76%) Compare
OPK OPKO Health, Inc. $1.3B — (loss-making) — (loss-making) −56.87% (below 0%: shrinking) n/m −3.40% (below 0%: shrinking) 64.30% (48.02%) Compare
FRNM Freenome, Inc $1.1B — (loss-making) — — n/m +12.06% (above 0%: growing) — 0.00% Compare
CSTL Castle Biosciences, Inc. $1.0B — (loss-making) — (loss-making) +23.90% (above 0%: growing) n/m +56.82% (above 0%: growing) 76.75% (2.65%) Compare
Median of peers $1.8B — — +15.08% +62.50% −6.51% 70.58% (1.59%)

All 49 Diagnostics & Research stocks →

Pay and ownership Proxy statement filed 6 April 2026

Ownership

Directors and executive officers, together 1.10%
BlackRock, Inc. 14.50%
Brown Advisory Incorporated 7.30%
First Light Asset Management, LLC 7.30%
Greenhouse Funds LLLP 5.70%
Millennium Management LLC 5.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

NeoGenomics, Inc. (NEO) Latest News

3 Nov

Impact 3 · · StockStory

31 Oct

Impact 3 · · StockStory

29 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · MarketBeat transcript
Impact 4 · · The Motley Fool transcript

28 Oct

Impact 4 · · StockStory earnings
Impact 4 · · Business Wire earnings
Impact 3 · · Zacks
Impact 3 · · Associated Press

27 Oct

Impact 3 · · StockStory

15 Oct

Impact 4 · · Business Wire

14 Oct

Impact 3 · · Business Wire

6 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · StockStory
Impact 3 · · TIKR

5 Oct

Impact 4 · · Business Wire
Impact 3 · · Investing.com

22 Sep

Impact 4 · · Simply Wall St.
Impact 3 · · StockStory

21 Sep

Impact 4 ·

20 Sep

Impact 4 · · MarketBeat

3 Sep

Impact 4 ·

2 Sep

Impact 3 ·

27 Aug

Impact 4 · · Barchart

26 Aug

Impact 4 ·

7 Aug

Impact 4 ·

3 Aug

Impact 3 ·

29 Jul

Impact 4 ·

28 Jul

Impact 3 · · MarketBeat transcript
Impact 3 ·

NEO metrics, ten years each

stockrow.com/NEO · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com